Literature DB >> 11314021

Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality.

T Rozovskaia1, E Feinstein, O Mor, R Foa, J Blechman, T Nakamura, C M Croce, G Cimino, E Canaani.   

Abstract

Rearrangements of the human ALL-1 gene are frequently encountered in acute lymphocytic leukemias (ALL) and acute myeloid leukemias (AML). These rearrangements are mostly due to chromosome translocations and result in production of chimeric proteins composed of the N-terminal fragment of ALL-1 and the C-terminal segments of the partner proteins. The most common chromosome translocation involving ALL-1 is the t(4 : 11) associated with ALL. ALL-1 is the human homologue of Drosophila trithorax and directly activates transcription of multiple Hox genes. A preliminary DNA microarray screen indicated that the Meis1, HoxA9 and AC133 genes were overexpressed in ALLs with t(4 : 11), compared to ALLs with very similar phenotype but without the chromosomal abnormality. These genes, as well as additional five Hox genes, were subjected to comprehensive semi-quantitative or quantitative RT-PCR analysis in 57 primary ALL and AML tumors. Meis1 and HoxA9 were found expressed in 13/14 of ALLs with the t(4 : 11) and in 8/8 of AMLs with ALL-1 rearrangements. The two genes were not consistently transcribed in other types of ALL. AC133 was transcribed in 13/14 of ALLs with t(4 : 11), but in only 4/8 of AMLs with ALL-1 rearrangements. HoxA10 was expressed in most leukemias with ALL-1 alterations, but was also transcribed in PrePreB CD10(-) ALLs lacking the t(4 : 11). Expression of HoxA5, HoxA7, HoxC8 and HoxC10 did not correlate with ALL-1 rearrangements. Coexpression of Meis1 and HoxA9, overexpression of HoxA10, and overexpression or fusion of HoxA9 were previously implicated in certain acute myeloid leukemias in mice and humans. The present work suggests that upregulation of Meis1, HoxA9, and possibly HoxA10 might also play a role in pathogenesis of acute lymphocytic and acute myeloid leukemias associated with ALL-1 fusions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11314021     DOI: 10.1038/sj.onc.1204174

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  55 in total

1.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

2.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

3.  Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation.

Authors:  Kira Orlovsky; Alexander Kalinkovich; Tanya Rozovskaia; Elias Shezen; Tomer Itkin; Hansjuerg Alder; Hatice Gulcin Ozer; Letizia Carramusa; Abraham Avigdor; Stefano Volinia; Arthur Buchberg; Alex Mazo; Orit Kollet; Corey Largman; Carlo M Croce; Tatsuya Nakamura; Tsvee Lapidot; Eli Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

4.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.

Authors:  Paul M Ayton; Michael L Cleary
Journal:  Genes Dev       Date:  2003-09-02       Impact factor: 11.361

5.  Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein.

Authors:  Paul M Ayton; Everett H Chen; Michael L Cleary
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

6.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Authors:  Jolanta Grembecka; Shihan He; Aibin Shi; Trupta Purohit; Andrew G Muntean; Roderick J Sorenson; Hollis D Showalter; Marcelo J Murai; Amalia M Belcher; Thomas Hartley; Jay L Hess; Tomasz Cierpicki
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

7.  The role of menin in hematopoiesis.

Authors:  Ivan Maillard; Jay L Hess
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

8.  The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Authors:  Eytan M Stein; Guillermo Garcia-Manero; David A Rizzieri; Raoul Tibes; Jesus G Berdeja; Michael R Savona; Mojca Jongen-Lavrenic; Jessica K Altman; Blythe Thomson; Stephen J Blakemore; Scott R Daigle; Nigel J Waters; A Benjamin Suttle; Alicia Clawson; Roy Pollock; Andrei Krivtsov; Scott A Armstrong; Jorge DiMartino; Eric Hedrick; Bob Löwenberg; Martin S Tallman
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

9.  HOX expression patterns identify a common signature for favorable AML.

Authors:  M Andreeff; V Ruvolo; S Gadgil; C Zeng; K Coombes; W Chen; S Kornblau; A E Barón; H A Drabkin
Journal:  Leukemia       Date:  2008-07-31       Impact factor: 11.528

10.  Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.

Authors:  Nilda L Alicea-Velázquez; Stephen A Shinsky; Daniel M Loh; Jeong-Heon Lee; David G Skalnik; Michael S Cosgrove
Journal:  J Biol Chem       Date:  2016-08-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.